Granted Patent B2

US 12,331,033 · App. 17/404,523 · Granted Jun 17, 2025

Inventors: Jonathan Bentley (Abingdon, GB); Todd Bosanac (New Milford, CT); Andrew Simon Brearley (Abingdon, GB); Sophie Catherine Cooper (Abingdon, GB); Rajesh Devraj (Chesterfield, MO); Robert Owen Hughes (Newtown, CT); Richard Andrew Jarjes-Pike (Abingdon, GB); Frederic Jacques Marlin (Abingdon, GB); Shelley Anne Parrott (Abingdon, GB); Daniel Silva (Abingdon, GB)

Assignee: Disarm Therapeutics, Inc.

C07D401/14C07D401/04C07D403/04C07D405/14C07D409/14C07D413/14C07D417/04C07D471/04C07D491/052C07D495/04C07B2200/05

Abstract

Claims (10)

1. A compound which is:

or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1 which is:

3. A pharmaceutical composition, comprising a compound of formula:

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

4. A method of inhibiting SARM1, comprising administering to a subject in need thereof, a compound of formula:

or a pharmaceutically acceptable salt thereof,

wherein the subject suffers from diabetic neuropathy or chemotherapy-induced peripheral neuropathy that is mediated by SARM 1.

5. The method according to claim 4 wherein the disease or disorder is chemotherapy-induced peripheral neuropathy.

6. The method according to claim 4 wherein the disease or disorder is diabetic neuropathy.

Assignments (4)

Continuity (4)

References Cited (33)